101.72 0.00 (0.00%)
After hours: 5:47PM EST
|Bid||101.79 x 200|
|Ask||102.19 x 200|
|Day's Range||101.27 - 102.86|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||23.84|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Depositary shares of the up-and-coming Chinese biotech firm BeiGene (BGNE) jumped 15% today, to $118, after the company successfully raised $750 million in a follow-on share offering. BeiGene has promising drugs under development, ample funding, and international partners like Celgene (CELG) and Boehringer Ingelheim. The Beijing-based drug developer is one of China’s leading hopes as that country tries to become one of the world’s medical innovators.
While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.
Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.
Mott Capital Management is a thematic growth fund that was founded in 2014 by Michael J. Kramer. Mr. Kramer manages a long-only thematic growth portfolio that has a stead and low turnover rate and contains an average of 20 stocks that are held over a period of up to five years. In addition to investing money on behalf […]
Stocks had a huge day, sending the major indexes to new records. Shares of Juno Therapeutics soared following a buyout report, and Ford slumped on disappointing guidance.
Shares of Juno Therapeutics Inc (NASDAQ: JUNO ) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG ) for an acquisition. ...
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.
Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.
Share of Juno Therapeutics (JUNO) have surged nearly 50% on Tuesday, on rumors that it's in talks with Celgene (CELG). Reports broke late Tuesday that Celgene was considering buying Juno, which would be its second deal in as many weeks. Celgene and other big biotechs are certainly pressed to do deals to keep their growth profiles up, although the rally in the sector, especially smaller names, means that prices are high.
Juno Therapeutics Inc (NASDAQ:JUNO) is up an astonishing 50% this morning on the headline that it’s in talks for a buyout from Celgene Corporation (NASDAQ:CELG). Rarely do we see a move of this size, but it’s apt that it is happening in the biotech sector, which is notorious for big headlines. At $70, JUNO is now trading 7% above the highest of their price targets and 25% above their average.
Learn about Celgene Corporation and its key financial ratios, such as the debt-to-equity (D/E) ratio, operating margin and return on invested capital (ROIC).
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.